Share on StockTwits

Shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have received a consensus recommendation of “Hold” from the sixteen analysts that are currently covering the company, AnalystRatingsNetwork.com reports. Four investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating on the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $26.79.

Auxilium Pharmaceuticals (NASDAQ:AUXL) opened at 20.06 on Tuesday. Auxilium Pharmaceuticals has a 52-week low of $16.36 and a 52-week high of $32.89. The stock has a 50-day moving average of $21.15 and a 200-day moving average of $24.3. The company’s market cap is $1.008 billion.

Auxilium Pharmaceuticals (NASDAQ:AUXL) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.22. The company had revenue of $8.50 million for the quarter, compared to the consensus estimate of $89.20 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. The company’s quarterly revenue was up 33.7% on a year-over-year basis. Analysts expect that Auxilium Pharmaceuticals will post $-0.17 EPS for the current fiscal year.

A number of research firms have recently commented on AUXL. Analysts at Aegis initiated coverage on shares of Auxilium Pharmaceuticals in a research note on Thursday, June 26th. They set a “buy” rating and a $37.00 price target on the stock. Separately, analysts at MKM Partners upgraded shares of Auxilium Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Wednesday, May 28th. They now have a $26.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at TheStreet downgraded shares of Auxilium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd.

Auxilium Pharmaceuticals, Inc is a specialty biopharmaceutical company focuses on developing and marketing products to predominantly specialist audiences.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.